NAD+ and NMN for Brain Health: Research, Mechanisms, and What the Evidence Shows

Few molecules in modern longevity science have generated as much attention — and as much overstatement — as NAD+ and its precursors NMN and NR. The mechanistic case for supporting NAD+ in the ageing brain is genuinely compelling. The human cognitive endpoint data, however, is still early. This article walks through both sides honestly: the biology that makes NAD+ central to neuronal energetics and repair, the precursors competing for clinical relevance, the human trials we actually have, and the cofactor and testing context most discussions skip.

What NAD+ actually is

Nicotinamide adenine dinucleotide (NAD+) is a small dinucleotide that participates as a coenzyme or substrate in more than 500 enzymatic reactions across human metabolism. In its oxidised (NAD+) and reduced (NADH) forms, it functions as the redox cofactor that drives glycolysis, the Krebs cycle, and electron transport chain complex I — the machinery that turns glucose, fatty acids, and amino acids into ATP. Without adequate NAD+, mitochondrial respiration collapses.

But NAD+ is not only a redox shuttle. It is also a consumed substrate for three classes of enzymes that govern stress response, DNA repair, and gene expression:

Sirtuins (SIRT1, SIRT3, SIRT6, SIRT7) — NAD+-dependent deacetylases that regulate mitochondrial biogenesis (via PGC-1α), inflammatory tone, and gene-silencing through histone modification. SIRT3 is the principal mitochondrial sirtuin and is heavily expressed in neurons.
PARPs (poly-ADP-ribose polymerases) — DNA-damage sensors that polymerise ADP-ribose chains onto repair targets, burning NAD+ in the process. Chronic DNA damage from oxidative stress keeps PARPs hyperactive.
CD38 — a glycohydrolase expressed on immune and glial cells that degrades NAD+ at high rates. CD38 activity rises with age, particularly in tissues with chronic low-grade inflammation.

Every NAD+ molecule consumed by sirtuins, PARPs, or CD38 must be replaced. That replacement is the entire point of supplementation strategies built around NMN, NR, and niacinamide.

The salvage pathway and why precursors matter

The body makes NAD+ through three pathways. The de novo route from tryptophan via the kynurenine cascade is metabolically expensive and contributes only a small fraction of daily NAD+ turnover in most tissues. The Preiss-Handler pathway uses dietary nicotinic acid (niacin). The dominant route — and the one that supplementation targets — is the salvage pathway:

Nicotinamide → NMN → NAD+ (via NAMPT, then NMNAT1/2/3)

Nicotinamide riboside (NR) enters this pathway one step earlier, being phosphorylated to NMN by NRK1/NRK2 kinases. NMN is then converted to NAD+ by NMNAT enzymes — NMNAT2 is the neuronal isoform, and its loss is a recognised driver of axonal degeneration. This is one mechanistic anchor for why NAD+ availability is brain-relevant rather than just systemic.

The age-related NAD+ decline

Work from Eric Verdin's group at the Buck Institute, Shin-ichiro Imai at Washington University, and David Sinclair's lab at Harvard has converged on a consistent picture: tissue NAD+ falls with age. Estimates from Verdin and others place brain NAD+ declines in the range of 30–50% by age 60 compared with young adult levels, depending on region and measurement technique. Three age-related forces compound the loss:

NAMPT expression falls — the rate-limiting enzyme of the salvage pathway is itself downregulated with age, particularly in the hypothalamus.
CD38 rises — chronic inflammaging upregulates CD38 on macrophages and microglia, accelerating NAD+ degradation. Imai's group has shown CD38 inhibition restores NAD+ in aged mice.
PARP overactivation — accumulated DNA damage keeps PARP1 chronically active, draining NAD+ pools from the nucleus outward.

The net result is a slow strangulation of sirtuin-dependent processes: mitochondrial biogenesis declines, mitophagy slows, oxidative stress responses blunt, and the energetic margin neurons depend on shrinks.

Why this matters specifically for the brain

Neurons are uniquely vulnerable to NAD+ shortfall. They are post-mitotic, highly oxidative, and depend on mitochondrial ATP for synaptic transmission, axonal transport, and ion-gradient maintenance. Several brain-specific NAD+ dependencies are now reasonably well characterised in animal models:

Mitochondrial biogenesis via SIRT3 and PGC-1α — both require NAD+ availability. Restoring NAD+ in aged mice improves mitochondrial function in cortex and hippocampus. Botanical adaptogens such as cordyceps are sometimes combined with NAD+ precursors in longevity stacks precisely because they target mitochondrial ATP output through complementary, non-overlapping pathways. See our overview on mitochondria and cognitive performance for context on why this energetic baseline matters for sustained cognition.
BDNF expression — sirtuin signalling intersects with the CREB pathway that drives BDNF transcription. This is one of the more interesting indirect routes by which NAD+ may support neuroplasticity. The deeper mechanism is covered in our BDNF guide.
Alpha-synuclein clearance — SIRT1 and SIRT3 promote autophagy and mitophagy, which clear misfolded proteins implicated in Parkinson's disease. NAD+ precursor work in PD models (Schöndorf et al., 2018) showed reversal of mitochondrial deficits in patient-derived iPSC neurons.
Tau phosphorylation — sirtuin activity modulates GSK-3β and CDK5, two kinases that hyperphosphorylate tau in Alzheimer's pathology. Sinclair-lab work in AD mouse models has shown NMN administration reduces tau pathology and improves cognitive performance.
Blood-brain barrier integrity — endothelial SIRT1 supports tight-junction maintenance. Loss of NAD+ in cerebral endothelium correlates with BBB leakiness in aged animals.

This is the mechanistic case. It is real, it is replicated, and it explains why NAD+ has become a focal point in neurodegeneration research. What it does not do is prove that taking 500 mg of NMN as a healthy 40-year-old will measurably improve your cognition.

The precursor field: NR, NMN, and the older niacins

Nicotinamide riboside (NR)

Discovered as a vitamin precursor by Charles Brenner in 2004, NR was the first salvage-pathway precursor to reach commercial scale. It is sold most prominently as Tru Niagen by ChromaDex. Human pharmacokinetic work from Brenner et al. (2018) and Conze et al. (2019) established that oral NR raises whole-blood NAD+ by roughly 40–60% at doses of 250–500 mg/day, with dose-dependence holding up to about 1 g/day. Most NR efficacy data sits in muscle (Martens 2018, Dolopikou 2020), skin, and metabolic markers. Direct human brain NAD+ measurement on NR is sparse — MRS-based studies are emerging but not yet definitive.

Nicotinamide mononucleotide (NMN)

NMN sits one step further down the salvage pathway and has become the centrepiece of David Sinclair's longevity work. Pharmacokinetic studies — notably Mills et al. (2016) in mice and human work from the Yoshino, Imai, and Klein groups — show NMN is rapidly absorbed and converted, though the question of whether NMN is dephosphorylated to NR at the brush border before re-phosphorylation inside cells (the Slc12a8 transporter debate) is not fully resolved. Sublingual and liposomal preparations exist, but the bioavailability advantage over standard oral NMN is not robustly demonstrated in humans.

Niacin and nicotinamide

The original B3 vitamers. Niacin (nicotinic acid) raises NAD+ effectively but causes the well-known prostaglandin-mediated flush at therapeutic doses. Nicotinamide (niacinamide) is well tolerated, cheap, and effective at raising NAD+ — but at high doses (above ~1–2 g/day) it can act as a sirtuin inhibitor through product inhibition, partially defeating the purpose. This is the main argument for using NR or NMN over plain nicotinamide despite the cost differential.

Comparison table

| Precursor | Typical dose | NAD+ rise (whole blood) | Brain-specific human data | Approx. monthly cost (AUD) | |---|---|---|---|---| | Niacin | 100–500 mg | 30–50% | Minimal | $5–15 | | Nicotinamide | 250–1000 mg | 30–60% | Minimal; sirtuin inhibition risk >1 g | $10–20 | | NR | 250–500 mg | 40–60% | Limited; muscle/skin dominant | $60–100 | | NMN | 250–500 mg | 30–50% | Animal-strong; human cognitive data emerging | $50–120 |

Numbers are research-grade approximations from the cited PK literature; individual response varies considerably with age, baseline NAD+, and CD38 status.

What the human trials actually show

This is where honesty is required. Most NAD+ precursor trials measure metabolic, vascular, or muscle endpoints — not brain function — and the cognitive trials we have are small and short.

Yoshino et al. (2021, Science) — 25 postmenopausal women with prediabetes, 250 mg/day NMN for 10 weeks. Primary finding was improved muscle insulin sensitivity. No cognitive endpoints.
Liao et al. (2021) — Chinese amateur runners, 300–1200 mg/day NMN for 6 weeks. Improved aerobic capacity at higher doses. Not a cognitive study.
Martens et al. (2018, Nature Communications) — middle-aged adults, 1 g/day NR for 6 weeks. Reduced systolic blood pressure and aortic stiffness. Vascular, not cognitive.
Wei et al. (2022) — small Chinese trial of NMN with reported improvements in Pittsburgh Sleep Quality Index and self-reported cognitive measures. Underpowered, single-blind elements, and not yet replicated in a larger Western cohort.
NR in Parkinson's (NR-SAFE / NADPARK trials, Tysnes group, Norway) — early-phase work showing NR raises cerebral NAD+ measured by MRS and shifts mitochondrial gene expression. Clinical signal is suggestive but not yet definitive on motor or cognitive outcomes.

Bottom line: the mechanistic and animal data are strong, the vascular and metabolic human data are reasonable, and the direct cognitive-endpoint data in healthy humans is preliminary. Anyone selling NMN as a confirmed cognitive enhancer is ahead of the evidence.

For comparison with research-stage neuroprotective compounds approached the same way — strong mechanism, emerging human data — see our writeup on Dihexa and cognitive neuroprotection research and the broader NAD+ brain health overview on this site.

Cofactors that change the equation

NAD+ supplementation is rarely a clean single-input system. Several cofactors materially change either NAD+ retention or downstream sirtuin activity:

Apigenin — a flavonoid CD38 inhibitor. By slowing NAD+ degradation, apigenin can extend the half-life of NAD+ raised by precursor supplementation. Verdin's group has highlighted CD38 inhibition as potentially more impactful than precursor loading in older adults.
Pterostilbene and resveratrol — sirtuin activators (specifically SIRT1). Sinclair has long argued for combining a precursor with a sirtuin activator on the basis that simply having more NAD+ doesn't help if SIRT1 isn't engaged. Pterostilbene has better oral bioavailability than resveratrol and forms the basis of the original Basis formulation.
Trimethylglycine (TMG / betaine) — a methyl donor. NAD+ precursor metabolism generates methylated nicotinamide (MeNAM) for excretion, and chronic high-dose precursor use can deplete S-adenosyl-methionine (SAM) pools. Stacking 500–1000 mg TMG with NMN/NR is now standard practice in informed longevity protocols. The methylation cost is real and under-discussed — tracking homocysteine is the most practical way to monitor whether methyl-donor support is adequate, since elevated homocysteine is a downstream signal of SAM depletion in the methylation cycle.
Magnesium and B-vitamin status — required cofactors for NAMPT and NMNAT enzymes. Suboptimal status blunts salvage-pathway flux regardless of how much precursor you take.

For people stacking NAD+ work into a broader cognitive protocol, the nootropics for programmers cognitive stack covers how these layer with cholinergic, BDNF, and mitochondrial-support compounds.

Testing NAD+ levels in Australia

Whole-blood NAD+ measurement is technically demanding. Specialist labs use HPLC or LC-MS to quantify NAD+, NADH, NMN, and methylated metabolites. In Australia, options include:

Jinfiniti (international shipping) — dried blood spot assay, around AUD $250–400.
Selected Australian functional medicine labs — pricing typically AUD $200–400, though availability fluctuates.
NAMPT enzyme activity — research-only; not clinically available.

A baseline plus a 12-week post-supplementation reading is the minimum useful pattern. Single point-in-time measurements without a baseline are largely uninterpretable.

Regulatory context

The regulatory status of NMN in particular has been turbulent. In 2022 the FDA stated NMN was no longer admissible as a dietary supplement ingredient in the United States (on the grounds it had been authorised for investigation as a drug), creating significant disruption for US-based brands. Subsequent legal and lobbying action has muddied the picture, but the position has not been cleanly reversed.

In Australia, the TGA treats NMN and NR within the broader complementary-medicines framework. Products are commercially available, and Australian customers generally retain reasonable access via domestic and international suppliers. NR remains less regulatory-contested than NMN globally.

For research-focused readers interested in how NAD+ biology overlaps with the broader peptide and longevity research field — including mitochondrial peptides like MOTS-c, SS-31, and Humanin — the longevity and NAD+ peptide research library at OzPeps catalogues Australian research-supplied compounds in that space.

Where this leaves the practical question

A balanced reading of the evidence as of 2026 looks roughly like this:

NAD+ decline with age is real, brain-relevant, and well-characterised.
Precursor supplementation (NR, NMN) reliably raises whole-blood NAD+ in human trials.
Brain NAD+ rises measurably on NR (NADPARK MRS data) — direct human MRS data on NMN crossing into brain is thinner.
Animal cognitive data is strong, particularly in AD and PD models.
Human cognitive endpoint data is preliminary; the strongest human signals are vascular and metabolic.
CD38 inhibition (apigenin) and methyl-donor support (TMG) are non-trivial adjuncts that most users ignore.

The honest framing for a 45-year-old researcher considering NMN or NR is not "this will sharpen my cognition" but rather "this is a mechanistically rational, low-risk intervention to support an energetic and stress-response system that is provably declining, with cognitive benefits that are plausible but not yet demonstrated in trials of my demographic." That framing is defensible. Stronger claims are not.

FAQ

Is NMN better than NR for the brain?

The honest answer is we don't know yet. NMN's case rests on being one step closer to NAD+ in the salvage pathway and Sinclair-lab animal data showing brain penetrance. NR's case rests on more mature human pharmacokinetic data and the only published human MRS evidence of cerebral NAD+ rise (NADPARK, Tysnes group). For brain-specific endpoints in humans, NR currently has a slight evidence lead. For systemic NAD+ raising, both work at appropriate doses. Cost, regulatory access, and personal response often matter more than the precursor choice itself.

What dose of NMN or NR is supported by trials?

Published trials cluster around 250–500 mg/day for both NMN and NR, with some protocols going to 1 g/day. Below 250 mg the NAD+ rise is small; above 1 g the marginal benefit appears limited and methylation cost increases. Most informed users settle in the 300–600 mg/day range, taken in the morning, with TMG support and ideally with a CD38 inhibitor like apigenin. Higher doses are not clearly better and increase the methyl-donor depletion risk.

Can I just take cheap nicotinamide instead?

You can — and you'll raise NAD+. The catch is that nicotinamide at doses above roughly 1–2 g/day acts as a sirtuin inhibitor through product feedback, which partially undermines the downstream benefit. At lower doses (250–500 mg/day) plain nicotinamide is a defensible, inexpensive choice, particularly for budget-conscious users who don't want to pay the NR/NMN premium. It just isn't as clean a tool for sirtuin-targeted intervention as NR or NMN.

Will I feel anything from taking NMN?

Most people feel nothing acutely, and that is expected. NAD+ supplementation is not a stimulant or mood-altering compound — it shifts metabolic and redox baselines over weeks. Some users report subjective improvements in energy, sleep, or recovery within 4–8 weeks. Many report nothing subjective at all, which does not necessarily mean it isn't working at the cellular level. If you want to track effect objectively, a baseline NAD+ blood test plus a 12-week follow-up is more informative than subjective impression.

Is NMN safe long-term?

Short-term human trials (up to 12 weeks at 250–1200 mg/day) have shown excellent tolerability with no significant adverse events. Long-term (multi-year) human safety data does not yet exist. Theoretical concerns include sustained sirtuin activation potentially affecting cancer cell metabolism, methyl-donor depletion, and unknown effects on PARP-mediated DNA damage signalling. None of these have materialised in published trials so far, but absence of evidence at long timeframes is not evidence of absence. Conservative practice is to cycle (e.g., 5 days on, 2 days off) and pair with TMG.

Disclaimer

This article is for educational and research-context purposes only. It does not constitute medical advice and is not a substitute for consultation with a qualified healthcare practitioner. NAD+ precursors, peptides, and other compounds discussed may have regulatory restrictions in your jurisdiction. Doses, products, and combinations referenced reflect the published literature, not personalised clinical guidance. Always consult a doctor before beginning, modifying, or stopping any supplement, particularly if you have a medical condition, are pregnant or breastfeeding, or take prescription medications.